JW Lifescience Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	253,706	257,829	222,478	206,860	188,931	169,817
Other Revenue	-	-	-	-	-0	-0
Revenue	253,706	257,829	222,478	206,860	188,931	169,817
Revenue Growth	4.13%	15.89%	7.55%	9.49%	11.26%	-7.47%
Cost of Revenue	182,123	185,577	165,010	154,507	140,972	120,788
Gross Profit	71,583	72,252	57,468	52,353	47,959	49,029
Selling, General & Admin	29,844	30,542	16,518	15,100	13,358	12,908
Research & Development	5,465	5,550	4,030	5,161	5,737	6,242
Amortization of Goodwill & Intangibles	1,464	1,418	278.99	403.54	744.89	493.83
Other Operating Expenses	322.52	374.82	262.41	161.56	159.04	162.39
Operating Expenses	38,254	39,008	21,610	21,491	20,870	20,612
Operating Income	33,329	33,244	35,858	30,862	27,089	28,417
Interest Expense	-2,837	-2,837	-2,061	-2,693	-3,092	-1,281
Interest & Investment Income	610.42	610.42	1,506	1,130	1,087	130.36
Earnings From Equity Investments	-	-	10,392	6,489	-4,921	-4,780
Currency Exchange Gain (Loss)	580.94	580.94	-2,570	-651.41	329.73	-149.04
Other Non Operating Income (Expenses)	257.13	97.31	15,864	-1,251	296.71	-3,772
EBT Excluding Unusual Items	31,940	31,696	58,989	33,886	20,789	18,565
Gain (Loss) on Sale of Investments	-	-	46.49	-	-	-
Gain (Loss) on Sale of Assets	49.79	49.79	-9.2	-	-	1.71
Asset Writedown	-	-	-	-166.58	-7.42	-279.65
Other Unusual Items	-	-	-	-10.72	-	-
Pretax Income	31,990	31,745	59,027	33,708	20,782	18,287
Income Tax Expense	5,970	3,139	15,039	5,564	5,821	5,373
Net Income	26,020	28,606	43,988	28,144	14,961	12,914
Net Income to Common	26,020	28,606	43,988	28,144	14,961	12,914
Net Income Growth	-47.42%	-34.97%	56.29%	88.11%	15.86%	-25.36%
Shares Outstanding (Basic)	15	15	15	15	15	16
Shares Outstanding (Diluted)	15	15	15	15	15	16
Shares Change	-0.01%	0.01%	-0.01%	-	-0.61%	-1.61%
EPS (Basic)	1680.32	1847.38	2841.00	1817.55	966.21	828.84
EPS (Diluted)	1680.32	1847.38	2841.00	1817.55	966.00	828.84
EPS Growth	-47.41%	-34.97%	56.31%	88.15%	16.55%	-24.14%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	35,585	27,983	40,383	29,421	6,049	11,189
Free Cash Flow Per Share	2298.07	1807.14	2608.20	1900.03	390.67	718.13
Dividend Per Share	-	-	-	500.000	500.000	500.000
Dividend Growth	-	-	-	0%	0%	0%
Gross Margin	28.21%	28.02%	25.83%	25.31%	25.38%	28.87%
Operating Margin	13.14%	12.89%	16.12%	14.92%	14.34%	16.73%
Profit Margin	10.26%	11.09%	19.77%	13.61%	7.92%	7.60%
Free Cash Flow Margin	14.03%	10.85%	18.15%	14.22%	3.20%	6.59%
EBITDA	51,808	51,437	51,595	46,393	42,045	41,661
EBITDA Margin	20.42%	19.95%	23.19%	22.43%	22.25%	24.53%
D&A For EBITDA	18,479	18,193	15,737	15,531	14,956	13,245
EBIT	33,329	33,244	35,858	30,862	27,089	28,417
EBIT Margin	13.14%	12.89%	16.12%	14.92%	14.34%	16.73%
Effective Tax Rate	18.66%	9.89%	25.48%	16.51%	28.01%	29.38%
Advertising Expenses	-	1,721	1,564	1,731	1,605	1,666